Evidence Hub

Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations

Bahat G, Erdogan T, Ozturk S, Selcukbiricik OS, Ozkok S, Yavuz DG, Karan MA, Reginster JY

Drugs & aging, 2026

3 citations

Abstract

Older adults with diabetes mellitus, encompassing both type 1 diabetes (T1D) and type 2 diabetes (T2D), face a substantially elevated risk of fragility fractures, contributing significantly to morbidity and mortality in this vulnerable population. The underlying pathophysiology differs between the two types: T1D is typically characterized by reduced bone mineral density (BMD) stemming from insulinopenia, whereas T2D often presents with normal or even high BMD but compromised bone quality due to factors, including altered microarchitecture, accumulation of advanced glycation end products (AGEs), and low bone turnover. These distinct mechanisms create challenges for accurate fracture risk assessment, as standard tools such as dual-energy X-ray absorptiometry (DXA)-measured BMD and the Fracture Risk Assessment Tool (FRAX) often underestimate the true risk, particularly in T2D. Effective management necessitates a comprehensive, individualized approach. This includes optimizing glycemic control while minimizing hypoglycemia, implementing lifestyle modifications such as adequate nutrition (calcium, vitamin D, protein) and appropriate exercise, and crucially, proactive fall prevention strategies. Careful consideration must be given to the selection of antidiabetic medications, avoiding agents known to harm bone (e.g., thiazolidinediones) and preferring those with neutral or potentially beneficial skeletal effects (e.g., metformin, dipeptidyl peptidase-4 inhibitors [DPP-4i],…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free